KALA BIO, Inc. (NASDAQ:KALA) Insider Darius Kharabi Sells 2,021 Shares

KALA BIO, Inc. (NASDAQ:KALA) insider Darius Kharabi sold 2,021 shares of KALA BIO stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.63, for a total value of $15,420.23. Following the completion of the transaction, the insider now owns 67,807 shares of the company’s stock, valued at $517,367.41. This trade represents a 2.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

KALA BIO Trading Up 2.1 %

NASDAQ KALA opened at $7.69 on Wednesday. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.15 and a current ratio of 2.15. KALA BIO, Inc. has a one year low of $4.21 and a one year high of $9.25. The company has a 50-day simple moving average of $6.71 and a 200-day simple moving average of $6.32. The firm has a market capitalization of $35.45 million, a PE ratio of -0.62 and a beta of -2.11.

KALA BIO (NASDAQ:KALA) last issued its earnings results on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50. On average, equities analysts forecast that KALA BIO, Inc. will post -10.84 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of KALA BIO in a research report on Friday, November 15th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP purchased a new stake in shares of KALA BIO, Inc. (NASDAQ:KALA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for approximately 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th biggest holding. SR One Capital Management LP owned about 15.76% of KALA BIO as of its most recent filing with the Securities and Exchange Commission (SEC). 24.61% of the stock is owned by institutional investors.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.